Trials / Terminated
TerminatedNCT04232397
Anlotinib Treatment in Steroid Depenent/Refractory cGVHD
A Phase 2 Study of Anlotinib in Subjects With Steroid Depenent/Refractory Chronic Graft Versus Host Disease(cGVHD)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center, single arm, prospective, phase II clinical study. The main purpose of this study is to evaluate the efficacy and safety of anlotinib in the treatment of steroid dependent/refractory chronic graft-versus-host disease (cGVHD) after allogeneic peripheral blood stem cell transplantation (allo HSCT).
Detailed description
Anlotinib 8mg qd po for 6months if no progression in 4weeks or reach PR in 3months
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | anlotinib 8mg qd po |
Timeline
- Start date
- 2020-04-10
- Primary completion
- 2020-09-15
- Completion
- 2021-03-01
- First posted
- 2020-01-18
- Last updated
- 2021-03-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04232397. Inclusion in this directory is not an endorsement.